Zacks Investment Research lowered shares of Vernalis plc (NASDAQ:VNLPY) from a buy rating to a hold rating in a report released on Saturday morning.

According to Zacks, “Vernalis Group plc is a research and development-stage pharmaceutical company based in Oxford, UK, which is developing drugs for the treatment of unmet medical needs such as cancer and inflammatory and infectious diseases. The main technology platform is inhibition of metalloenzymes which will be supplemented through the addition of externally-generated programs. “

Vernalis plc (NASDAQ:VNLPY) opened at 0.56 on Friday. The company’s market cap is $147.40 million. Vernalis plc has a 1-year low of $0.47 and a 1-year high of $0.95. The stock has a 50 day moving average price of $0.58 and a 200 day moving average price of $0.58.

TRADEMARK VIOLATION NOTICE: “Vernalis plc (VNLPY) Downgraded by Zacks Investment Research” was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at

Vernalis plc Company Profile

Vernalis plc is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders.

Get a free copy of the Zacks research report on Vernalis plc (VNLPY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vernalis plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vernalis plc and related companies with's FREE daily email newsletter.